ChromoCure/Genome Research Group Issues Interim Investor Guidance on $29,000,000 Merger and Acquisition
May 10 2010 - 8:40AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) issued preliminary investor
guidance on its recently announced $29,000,000 Merger and
Acquisition of Genome Research Group.
Merger and Acquisition Agreement
On May 7, 2010, the Company completed the equity-based Merger
and Acquisition Agreement with Genome Research Group, a private
company that develops proprietary cancer analysis systems and
related therapeutic technologies and treatment protocols. The
transaction results in significant increases to shareholder equity
and reductions in long-term liabilities.
The transaction is valued at $29,000,000 representing the
valuation of the GRG operations and assets, including GRG's
proprietary advanced therapeutic modeling protocols and algorithms
utilizing hypothermic modulation and resonance. Included also is
GRG's therapeutic results and findings, methodologies and
proprietary knowledge in the non-toxic and non-invasive treatment
of cancer.
Merged Operations, Capabilities and
Direction
The amalgamated company will:
- Operate under new GRG management;
- Integrate both Companies' operations and Intellectual Property
(IP) assets;
- Be renamed Genome Research Group;
- Move its main operations to GRG's base in London, UK.;
- Continue its collaboration and research initiatives in the
United States as well as expanding these efforts throughout
Europe;
- Possess complementary detection and therapeutic technology and
protocols, comprised of ChromoCure's advanced detection system and
GRG's full line of therapeutic protocols and technology;
- Possess the first time real-time progression monitoring and
remission detection;
- Provide the world's first cure research fully integrated system
for the precise measurement of treatment and results;
- Establish a worldwide network of diagnostic and research
collaborations with continuous collection of cancer specimen and
test result data.
Future Updates
Investors can anticipate updates on the following:
- Elimination of prior corporate debt and addition of new
technology assets.
- Appointment of industry professionals to the Company's Advisory
and Business Development Boards.
- New additions and expansions to the Company's Intellectual
Property assets
- New technology and Joint Development agreements and status
reports on current projects
- Full business plan information and regular technology briefings
on the company's technology development, licensing and
distribution
- Full disclosure documents and financials posted with the OTC
Disclosure Service
- Further updates on research collaborations, laboratory
partnerships, and research initiatives, including the expansion of
Pathologist Collaborative Research (PCR) program in North America,
the Euro Zone and the rest of the world
- Continue support of the groundbreaking Project Boveri: Find the
Cure Initiative
Financial Reporting and Regular
Disclosures
The Company believes transparency is essential to an orderly and
healthy market in its stock. The updated financials reflecting the
$29 million asset acquisition, merger and resultant share
restructuring, together with updates on name change, new website
and other operational updates will be released as part of the
Company's ongoing OTC disclosure practices.
SEC "Fully reporting" and regular SEC
filings
The Company does not intend to become a "SEC fully reporting"
company and subject itself to the burden of SEC filings. The
Company believes the massive time and cost burdens of maintaining
SEC filings are a material threat to the company's operations and
profitability. The company will maintain public disclosures that
meet or exceed SEC 'reporting' criteria.
Revenue Projections and Market
Analysis
The Company receives many inquiries regarding its technology,
sales projections, and market strategy. The Company intends to
disclose and make public several important components of its
business plan combined with technology overviews and project
updates. These disclosures will contain various analyses of
specific sectors of the industries we target. Contained within the
market surveys and analyses will be revenue projections. Upon
release of the disclosures and posting on the Company's web site,
they will be filed with the OTC Disclosure Service to ensure all
investors access to current information.
Recent Stock Price and Market
Valuation
Many stockholders have queried the Company's recent low stock
price. The Company has only recently revised and expanded its
business plan after a lengthy overhaul of operations. The Company's
current share price may not be an accurate reflection of the
company's actual value. The Company believes its market
capitalization will steadily, and perhaps dramatically, improve
with each passing week as more learn of the company's technology,
vision, and its performance.
Management believes the transaction to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation; as the companies leverage their combined
technologies, research knowledge and industry relationships.
About Genome Research Group, Inc.
The Company develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristics found in 100% of all cancers and never
found in normal cells. The Company's detection technology has a
proven and effective accuracy of 100% for all cancers at all
stages. The Company's proprietary Therapeutic Modeling Protocols
provide statistical modeling and prediction tools for the
measurement and monitoring of cancer progression and remission. The
Company also applies its technology and knowledge to cancer cure
and therapeutics research. The Company owns proprietary cancer
detection systems and related therapeutic technologies and
proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. GRG's advanced
Therapeutic Modeling and Treatment Protocols combined with its
industry and medical research collaborations validate its
leadership role in Cancer Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024